VSIR and leukemia: Evidence suggests that VISTA exerts an inhibitory effect on the anti-leukemia T-cell response, as demonstrated by the effective reduction of MDSC-mediated CD8+ T-cell inhibition in AML following VISTA knockdown using specific siRNA (145).